{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T20:37:38Z","timestamp":1788381458162,"version":"build-2803163510"},"reference-count":64,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bjoms.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["British Journal of Oral and Maxillofacial Surgery"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.bjoms.2020.11.008","type":"journal-article","created":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T06:53:08Z","timestamp":1605855188000},"page":"534-545","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Recent advances in the management of cutaneous malignant melanoma: our case cohort"],"prefix":"10.1016","volume":"59","author":[{"given":"A.","family":"Sayan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Plant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Eccles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Ilankovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bjoms.2020.11.008_bib0005","first-page":"215","article-title":"Malignant melanoma: prevention, early detection, and treatment in the 21st century","volume":"50","author":"Rigel","year":"2000","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0010","series-title":"Cutaneous melanoma: etiology and therapy","article-title":"Epidemiology of melanoma","author":"Matthews","year":"2017"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0015","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.amepre.2014.08.036","article-title":"Prevalence and costs of skin cancer treatment in the US, 2002-2006 and 2007-2011","volume":"48","author":"Guy","year":"2015","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0020","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/ije\/3.4.325","article-title":"Relationship of melanoma and other skin cancer mortality to latitude and ultraviolet radiation in the United States and Canada","volume":"3","author":"Elwood","year":"1974","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0025","doi-asserted-by":"crossref","first-page":"908","DOI":"10.3390\/ijerph16060908","article-title":"Race-, age-, and anatomic site-specific gender differences in cutaneous melanoma suggest differential mechanisms of early- and late-onset melanoma","volume":"16","author":"Yuan","year":"2019","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0030","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/her\/cyh010","article-title":"SunSmart? Skin cancer knowledge and preventative behaviour in a British population representative sample","volume":"20","author":"Miles","year":"2005","journal-title":"Health Educ Res"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0035","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1365-2133.2009.09459.x","article-title":"Skin cancer prevention in Australia","volume":"161 Suppl 3","author":"Sinclair","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0040","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jaad.2010.11.016","article-title":"Systematic skin cancer screening in Northern Germany","volume":"66","author":"Breitbart","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0045","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.1200\/JCO.2004.03.074","article-title":"Prognostic factors of thin cutaneous melanoma: an analysis of the central malignant melanoma registry of the German dermatological society","volume":"22","author":"Leiter","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0050","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1146\/annurev-pathol-012513-104658","article-title":"The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia","volume":"9","author":"Bastian","year":"2014","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0055","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrc.2016.37","article-title":"From melanocytes to melanomas","volume":"16","author":"Shain","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0060","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/CMR.0000000000000235","article-title":"Endothelin-1 in the tumor microenvironment correlates with melanoma invasion","volume":"26","author":"Chiriboga","year":"2016","journal-title":"Melanoma Res"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0065","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.3892\/or.2014.2977","article-title":"Analysis of the B-RafV600E mutation in cutaneous melanoma patients with occupational sun exposure","volume":"31","author":"Candido","year":"2014","journal-title":"Oncol Rep"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0070","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejcb.2014.01.002","article-title":"Metalloproteinases in melanoma","volume":"93","author":"Moro","year":"2014","journal-title":"Eur J Cell Biol"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0075","doi-asserted-by":"crossref","first-page":"933","DOI":"10.18632\/aging.100951","article-title":"MMP9 overexpression is associated with intragenic hypermethylation of MMP9 gene in melanoma","volume":"8","author":"Falzone","year":"2016","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0080","first-page":"1071","article-title":"Cutaneous melanoma: from pathogenesis to therapy (review)","volume":"52","author":"Leonardi","year":"2018","journal-title":"Int J Oncol"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0085","doi-asserted-by":"crossref","first-page":"135","DOI":"10.18632\/oncotarget.240","article-title":"Ras\/Raf\/MEK\/ERK and PI3K PTEN\/Akt\/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health","volume":"2","author":"Chappell","year":"2011","journal-title":"Oncotarget"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0090","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0046-8177(96)90157-4","article-title":"Discordance in the histologic diagnosis of melanoma and melanocystic nevi between expert pathologists","volume":"27","author":"Farmer","year":"1996","journal-title":"Hum Pathol"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035309","article-title":"Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials","volume":"7","author":"Lovly","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0100","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/ng.3361","article-title":"Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas","volume":"47","author":"Krauthammer","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0105","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1158\/2159-8290.CD-13-0017","article-title":"An unholy alliance: cooperation between BRAF and NF1 in melanoma development and BRAF inhibitor resistance","volume":"3","author":"Gibney","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0110","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1755-148X.2010.00671.x","article-title":"Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure","volume":"23","author":"Handolias","year":"2010","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0115","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/bjd.16892","article-title":"The new 8th edition of TNM staging and its implicatins for skin cancer: a review by the British Association of Dermatologists and the Royal College of Pathologists, U.K","volume":"179","author":"Keohane","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0120","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1001\/archsurg.1992.01420040034005","article-title":"Technical details of intraoperative lymphatic mapping for early stage melanoma","volume":"127","author":"Morton","year":"1992","journal-title":"Arch Surg"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0125","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1177\/0194599811408554","article-title":"Sentinel node biopsy for head and neck melanoma: a systematic review","volume":"145","author":"de Rosa","year":"2011","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0130","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.bjoms.2019.07.022","article-title":"Sentinel lymph node biopsy for melanoma of the head and neck: a multicentre study to examine safety, efficacy, and prognostic value","volume":"57","author":"Passmore-Webb","year":"2019","journal-title":"Br J Oral Maxillofac Surg"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0135","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.bjps.2019.06.020","article-title":"Current role of sentinel lymph node biopsy in the management of cutaneous melanoma: a UK consensus statement","volume":"73","author":"Peach","year":"2020","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0140","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","article-title":"Completion dissection or observation for sentinel-node metastasis in melanoma","volume":"376","author":"Faries","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0145","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(16)00141-8","article-title":"Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial","volume":"17","author":"Leiter","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0150","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/modpathol.2017.104","article-title":"Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine","volume":"31","author":"Cheng","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0155","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrc.2017.7","article-title":"Liquid biopsies come of age: towards implementation of circulating tumour DNA","volume":"17","author":"Wan","year":"2017","journal-title":"NAT Rev Cancer"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0160","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0165","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAF (V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0170","first-page":"8487","article-title":"Comparison between two widely used laboratory methods in BRAF V600 mutation detection in a large cohort of clinical samples of cutaneous melanoma metastases to the lymph nodes","volume":"8","author":"Jurkowska","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0175","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/DAD.0000000000000404","article-title":"BRAF-V600 mutation heterogeneity in primary and metastatic melanoma: a study with pyrosequencing and immunohistochemistry","volume":"38","author":"Yaman","year":"2016","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0180","doi-asserted-by":"crossref","first-page":"824","DOI":"10.3390\/cancers2020824","article-title":"Surgery of primary melanomas","volume":"2","author":"Rutkowski","year":"2010","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0185","doi-asserted-by":"crossref","first-page":"367","DOI":"10.6004\/jnccn.2019.0018","article-title":"Cutaneous melanoma, version 2.2019, NCCN Clinical Practice Guidelines in Oncology","volume":"17","author":"Coit","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0190","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0190-9622(18)30743-6","article-title":"Surgical margins for excision of primary cutaneous melanoma","volume":"37","author":"Zitelli","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0195","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.1200\/JCO.2006.06.0483","article-title":"Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group","volume":"24","author":"Bedikian","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0200","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1054\/bjoc.2000.1141","article-title":"Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine","volume":"82","author":"Propper","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0205","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1200\/JCO.2000.18.1.158","article-title":"Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma","volume":"18","author":"Middleton","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0210","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.ejca.2011.04.030","article-title":"Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032)","volume":"47","author":"Patel","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0215","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/00008390-200410000-00013","article-title":"The role of taxanes in the treatment of metastatic melanoma","volume":"14","author":"Gogas","year":"2004","journal-title":"Melanoma Res"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0220","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1093\/jnci\/85.8.622","article-title":"Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine- activated killer cells for the treatment of patients with advanced cancer","volume":"85","author":"Rosenberg","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0225","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1200\/JCO.2002.20.1.125","article-title":"Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma","volume":"20","author":"Agarwala","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0230","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0235","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0240","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0245","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1600-065X.2008.00662.x","article-title":"Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways","volume":"224","author":"Fife","year":"2008","journal-title":"Immunol Rev"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0250","doi-asserted-by":"crossref","first-page":"12400","DOI":"10.18632\/oncotarget.24249","article-title":"Effectiveness of anti-PD-1\/PD-L1 antibodies in urothelial carcinoma patients with different PD-L1 expression levels: a meta-analysis","volume":"9","author":"Liu","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0255","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1200\/jco.2012.30.18_suppl.lba8500","article-title":"Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAFV600E-mutated melanoma","volume":"30","author":"Hauschild","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0260","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","article-title":"Safety and efficacy of vemurafenib in BRAF (V600E) and BRAF (V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study","volume":"15","author":"McArthur","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0265","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Eng J Med"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0270","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0275","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0280","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0285","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0290","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0295","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III and IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0300","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Eng J Med"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0305","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0310","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0315","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.critrevonc.2017.01.017","article-title":"The synergistic effect of radiotherapy and immunotherapy: a promising but not simple partnership","volume":"111","author":"Chajon","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.bjoms.2020.11.008_bib0320","article-title":"Surgery versus stereotactic radiotherapy for people with single or solitary brain metastasis","volume":"8","author":"Fuentes","year":"2018","journal-title":"Cochrane Database Syst Rev"}],"container-title":["British Journal of Oral and Maxillofacial Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0266435620308949?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0266435620308949?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T15:29:17Z","timestamp":1759418957000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0266435620308949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":64,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0266435620308949"],"URL":"https:\/\/doi.org\/10.1016\/j.bjoms.2020.11.008","relation":{},"ISSN":["0266-4356"],"issn-type":[{"value":"0266-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in the management of cutaneous malignant melanoma: our case cohort","name":"articletitle","label":"Article Title"},{"value":"British Journal of Oral and Maxillofacial Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bjoms.2020.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2020 Published by Elsevier Ltd on behalf of The British Association of Oral and Maxillofacial Surgeons. All rights reserved.","name":"copyright","label":"Copyright"}]}}